Intestinal Current Measurements (ICM) to Evaluate the Activation of Mutant CFTR in Subjects With Cystic Fibrosis Aged 12 Years and Older, Homozygous for the p.Phe508del-CFTR Mutation, Treated With Lumacaftor in Combination With Ivacaftor
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Biomarker; Pharmacodynamics
- Acronyms OrkambiFacts
- 28 Jul 2020 Status changed from recruiting to completed.
- 22 Feb 2019 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 22 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2019.